The fact that follicular lymphoma is characterized by a specific immune phenotype and a nonrandom chromosomal translocation which may be detected at the molecular level makes it possible to design novel therapeutic strategies for curative therapy. Molecular markers may be used to test hypotheses. Some current causes for optimism are reviewed.